What the NHS-Galleri trial really tells us about multi-cancer early detection Despite missing its primary endpoint, the trial shows a substantial reduction in stage four cancers and earlier detection across multiple tumor types.

https://www.drugdiscoverynews.com/what-the-nhs-galleri-trial-really-tells-us-about-multi-cancer-early-detection-17106 When early readouts from the NHS-Galleri trial in February 2026 revealed that the study had missed its primary endpoint, headlines quickly framed the outcome as a setback for multi-cancer early detection (MCED). For a technology often positioned as a potential revolution in cancer screening, the reaction was swift and, in some cases, pessimistic.